{"nctId":"NCT00103662","briefTitle":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","startDateStruct":{"date":"2005-01"},"conditions":["Multiple Myeloma"],"count":302,"armGroups":[{"label":"G-CSF plus plerixafor","type":"EXPERIMENTAL","interventionNames":["Drug: Granulocyte colony-stimulating factor plus plerixafor"]},{"label":"G-CSF plus placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Granulocyte colony-stimulating factor plus placebo"]}],"interventions":[{"name":"Granulocyte colony-stimulating factor plus plerixafor","otherNames":["Mozobil","AMD3100"]},{"name":"Granulocyte colony-stimulating factor plus placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of multiple myeloma in first or second complete or partial remission\n* \\>= 4 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade were not considered prior chemotherapy for the purpose of this study)\n* Recovered from all acute toxic effects of prior chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* White Blood Cell count (WBC) \\> 2.5\\*10\\^9/L\n* Absolute polymorphonuclear leukocytes (PMN) count \\> 1.5\\*10\\^9/L\n* Platelet (PLT) \\> 100\\*10\\^9/L\n* Serum creatinine \\<=2.2 mg/dL\n* Cardiac and pulmonary status sufficient to undergo apheresis and transplantation\n* Negative for HIV\n\nExclusion Criteria):\n\n* Failed previous stem cell collection\n* Previous stem cell transplantation\n* Brain metastases or myelomatous meningitis\n* Radiation to ≥ 50% of the pelvis\n* Abnormal electrocardiogram (ECG) with rhythm disturbance (ventricular arrhythmias) or other conduction abnormality\n* Received bone-seeking radionuclides (e.g. holmium)\n* A residual acute medical condition resulting from prior chemotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.","description":"Proportion of participants achieving a target of ≥ 6\\*10\\^6 CD34+ cells/kg in 2 or fewer days of apheresis. Central lab data were taken from Days 5 to 6 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 2 apheresis days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.716","spread":null},{"groupId":"OG001","value":"0.344","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.284","spread":null},{"groupId":"OG001","value":"0.656","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.","description":"Proportion of participants achieving a target of ≥ 6\\*10\\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.757","spread":null},{"groupId":"OG001","value":"0.513","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.243","spread":null},{"groupId":"OG001","value":"0.487","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Target of ≥ 2*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.","description":"Proportion of participants achieving a target of ≥ 2\\*10\\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.953","spread":null},{"groupId":"OG001","value":"0.883","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.047","spread":null},{"groupId":"OG001","value":"0.117","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Number of Days to ≥6*10^6 CD34+ Cells/kg","description":"The Kaplan Meier estimate of median number of days (number of days at which 50% of participants have experienced the event, accounting for censored values) in each treatment arm to collect an optimum number of cells (≥6\\*10\\^6 CD34+ cells/kg) for transplantation.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment","description":"The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\\*10\\^9/L for 3 consecutive days or ≥ 1.0\\*10\\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Number of Days to Platelet (PLT) Engraftment","description":"The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\\*10\\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Durability at 100 Days Post Transplantation","description":"The proportion of participants maintaining a durable graft at 100 days post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \\>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \\>=10g/dL for at least 1 month, (3) and absolute neutrophil count \\>1000/µL for at least 1 week.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.986","spread":null},{"groupId":"OG001","value":"0.978","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":null},{"groupId":"OG001","value":"0.022","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Durability at 6 Months Post Transplantation","description":"The proportion of participants maintaining a durable graft at 6 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \\>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \\>=10g/dL for at least 1 month, (3) and absolute neutrophil count \\>1000/µL for at least 1 week.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.985","spread":null},{"groupId":"OG001","value":"0.984","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.015","spread":null},{"groupId":"OG001","value":"0.016","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Durability at 12 Months Post Transplantation","description":"The proportion of participants maintaining a durable graft at 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \\>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \\>=10g/dL for at least 1 month, (3) and absolute neutrophil count \\>1000/µL for at least 1 week.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.992","spread":null},{"groupId":"OG001","value":"0.992","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.008","spread":null},{"groupId":"OG001","value":"0.008","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":147},"commonTop":["Bone pain","Nausea","Fatigue","Diarrhoea","Paraesthesia"]}}}